Lannett Company Balanced Scorecard
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Dive Deeper Into the Growth Paths Behind the Analysis
This Lannett Company Balanced Scorecard Analysis gives you a clear, structured view of the company's financial, customer, internal process, and learning and growth priorities. The page already shows a real preview of the actual report content, so you can see what the analysis looks like before you buy. Purchase the full version to get the complete ready-to-use analysis.
Benefits
Margin Control
Margin control is central for Lannett Company because generic drugs sell under constant price pressure, so small shifts in unit cost and batch yield can move gross margin fast. The scorecard ties those inputs to margin, helping management separate real process gains from one-time price swings. In fiscal 2025, that matters even more as every point of yield or cost saved can protect profitability in a low-price market.
Quality Discipline
Quality discipline is a financial control at Lannett Company because fewer deviations, complaints, and slow CAPA closures mean fewer shipment holds, recalls, and FDA follow-up costs. In 2025, this matters even more in a tight generic-drug market where one batch delay can hit cash flow and margin fast. Better control speeds release, protects revenue, and lowers rework.
Supply Reliability
Supply reliability matters at Lannett Company because it develops, makes, packages, markets, and distributes products end to end. Fill rate, on-time-in-full delivery, and backlog age show whether plants and the supply chain can meet customer demand without delays. If these metrics stay strong, Lannett protects service levels, reduces stockouts, and keeps revenue timing more predictable.
Contract Service Clarity
For Lannett Company, contract service clarity helps turn each external account into a measured profit center. A balanced scorecard can link turnaround time, audit readiness, and customer response time to the real cost of each contract, so managers see where service delays eat margin. This matters in 2025 because FDA inspection findings still drive compliance risk, and faster issue closure lowers the chance of costly rework or account loss.
Portfolio Visibility
Portfolio visibility matters for Lannett Company because its cardiovascular, central nervous system, and pain management generics can perform very differently by product family. A scorecard lets management compare each line on margin, demand stability, and quality risk instead of masking weak SKUs inside a blended average. That is vital in generics, where one product can face sharp price erosion while another holds volume and still supports cash flow.
Lannett's 2025 Scorecard: Protect Margins, Fix Quality, and Steady Supply
For Lannett Company, the biggest benefits of a balanced scorecard in 2025 are tighter margin control, faster quality fixes, and steadier supply. Those gains matter because generics still face sharp price pressure, so small cuts in waste, delays, and rework can protect cash flow. It also helps leaders see which products and contracts earn real profit.
| Benefit | 2025 focus |
|---|---|
| Margin | Yield, cost, pricing |
| Quality | Deviations, CAPA, releases |
| Supply | Fill rate, backlog, OTIF |
What is included in the product
Detailed Word Document
Editable Excel File
Drawbacks
Data Complexity
Lannett Company's manufacturing, packaging, distribution, and contract work data often live in separate systems, so a balanced scorecard can take longer to build and update. That split raises the risk of mismatched KPIs, delayed reporting, and higher data-cleaning costs. In practice, even one late feed can skew inventory, yield, and on-time delivery views.
For a pharma maker, that hurts decision speed because leaders need one clean view of quality, supply, and cost at the same time.
Margin Blind Spots
Margin blind spots are a real risk for Lannett Company because a balanced scorecard can still look fine while cash flow weakens and pricing pressure builds. U.S. generic drugs fill about 90% of prescriptions but account for only about 13% of drug spending, so spreads are thin and can shrink fast. That means a small rebate, price cut, or mix shift can wipe out profit even when volume looks steady.
Regulatory Distortion
Regulatory distortion can swamp Lannett Company's balanced scorecard: one FDA inspection issue or quality event can overpower several healthy KPIs, making the trend look worse than the business really is. In 2025, regulators still tracked thousands of drug-site inspections and quality actions across the sector, so a single Form 483 or warning letter can quickly dominate management attention. That can push leaders to chase the metric, not fix the root cause.
Short Planning Horizon
Lannett Company's short planning horizon is a real weakness because generic pricing and demand can change in weeks, not quarters. A scorecard built on last quarter's assumptions can be stale by the next rebid, product cycle, or contract loss, so margin and cash targets may miss fast market shifts. In FY2025, that matters more because small changes in volume or average selling price can move results quickly.
Customer Concentration
Lannett Company faces customer concentration risk because contract manufacturing and generic drug sales can depend on a few buyers. If one customer cuts orders, service scores can stay strong while revenue and cash flow fall fast. In this model, a high fill-rate can mask a weak sales mix, so the scorecard needs customer-share and order-loss tracking, not just on-time delivery.
Lannett's Hidden Risks: Thin Margins, FDA Hiccups, and Data Silos
Lannett Company's scorecard can lag operations because manufacturing, packaging, and contract data sit in separate systems, so KPI updates are slower and less reliable. Generic-drug margins stay thin: generics fill about 90% of U.S. prescriptions but only 13% of drug spend, so small price or mix shifts can erase profit. FDA quality issues can also swamp the view, and a single action can outweigh several good metrics. Customer concentration adds more noise when one buyer cut can hit cash fast.
| Drawback | FY2025 risk |
|---|---|
| Data silos | Slower, mismatched KPIs |
| Thin margins | 90% volume, 13% spend |
| Regulatory events | One issue can dominate trends |
| Customer mix | Order loss can hit cash flow |
Full Version Awaits
Lannett Company Reference Sources
This is the actual Lannett Company Balanced Scorecard Analysis document you'll receive upon purchase – no sample, no placeholder. The preview below is pulled directly from the full report, so what you see here is the same professional document unlocked after checkout. Purchase gives you the complete, detailed version in full.
Frequently Asked Questions
It measures whether operating execution and financial results are moving together. For Lannett, the most useful indicators are gross margin, batch-release cycle time, and on-time-in-full delivery. Those 3 signals show whether the company is converting manufacturing discipline into service reliability and better economics, instead of relying on a single quarterly number.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.